

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date January 18, 2013

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment - Local Public / Health Practitioners**

The Department's method for class review are to better utilize the time of the P&T Committee.

Classes shown in **Red** are new classes or classes where **new information exists and public testimony will be taken. Public testimony will be taken for classes shown in **Blue** will only if **new information is received.

Classes shown in **Green**, no significant changes have been noted and no public testimony will be taken.

****New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.**

4. Public comment , discussion & vote on **Red Classes**

Re-Review: Angiotensin Modulators (Angiotensin II Receptor Blockers)	Review: Neuropathic Pain (previously “topical anesthetics” and “fibromyalgia”)
--	--

5. Public comment, discussion & vote **Blue Classes**

Re-Review: Beta Blockers	Re-Review: Hypoglycemics, Incretin Enhancers/Mimetics
Re-Review: Ulcerative Colitis Agents	Re-Review: Ophthalmic Glaucoma Agents

6. Discussion & vote on **Green Classes**

Re-Review: Angiotensin Modulators (ACE Inhibitors and Renin Inhibitors)	Re-Review: Calcium Channel Blockers
Re-Review: Topical Acne Agents	Re-Review: Immunomodulators, Atopic Dermatitis
Re-Review: Androgenic Agents	Re-Review: Hypoglycemics, Insulins
Re-Review: Hypoglycemics, Meglitinides	Re-Review: Hypoglycemics, Metformins
Re-Review: Hypoglycemics, Sulfonylureas	Re-Review: Hypoglycemics, Thiazolidinediones (TZDs)
Re-Review: Immunosuppressants	Re-Review: Smoking Cessation Agents

7. **Break as needed – 15 minutes**
8. **Review minutes from November 16, 2012 meeting**
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Next Meeting Date: April 19, 2013